Transgene SA
PAR:TNG

Watchlist Manager
Transgene SA Logo
Transgene SA
PAR:TNG
Watchlist
Price: 0.701 EUR -0.14%
Market Cap: 92.7m EUR
Have any thoughts about
Transgene SA?
Write Note

Transgene SA
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Transgene SA
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Transgene SA
PAR:TNG
Other Operating Expenses
-€37.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other Operating Expenses
€207.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Other Operating Expenses
€6.4m
CAGR 3-Years
-22%
CAGR 5-Years
-8%
CAGR 10-Years
3%
G
Genfit SA
PAR:GNFT
Other Operating Expenses
-€17.9m
CAGR 3-Years
-14%
CAGR 5-Years
-3%
CAGR 10-Years
-5%
Inventiva SA
PAR:IVA
Other Operating Expenses
-€671k
CAGR 3-Years
N/A
CAGR 5-Years
28%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other Operating Expenses
€229k
CAGR 3-Years
-9%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
No Stocks Found

Transgene SA
Glance View

Market Cap
92.7m EUR
Industry
Biotechnology

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

TNG Intrinsic Value
1.023 EUR
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Transgene SA's Other Operating Expenses?
Other Operating Expenses
-37.4m EUR

Based on the financial report for Sep 30, 2024, Transgene SA's Other Operating Expenses amounts to -37.4m EUR.

Back to Top